Middle East Journal of Cancer

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Editorial Board

Publication Ethics

Indexing and Abstracting

Related Links

FAQ

Peer Review Process

News

Forms

Journal Metrics

The Prognostic Significance of LVSI in Early-Stage Endometrioid Endometrial Cancer: Insights into Recurrence Patterns and Survival Outcomes

Articles in Press

Document Type : Original Article(s)

Authors

1 Department of obstetrics and gynecology, Shiraz university of medical sciences, Shiraz, Iran. Infertility Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

2 Department of Obstetrics and Gynecology, Shiraz University of Medical Sciences, Shiraz, Iran

3 Department of Obstetrics and Gynecology, Shiraz University of Medical Sciences, Shiraz, Iran. Department of Obstetrics and Gynecology, Division of Oncology Gynecology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

4 Department of Obstetrics and Gynecology, Division of Oncology Gynecology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. Maternal-Fetal Medicine Research Center, Department of Obstetrics and Gynecology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

10.30476/mejc.2026.105882.2252

Abstract

Background: Endometrioid endometrial cancer (EEC) is a significant disease among women worldwide. The present study aimed to investigate the role of lymphovascular space invasion (LVSI) detection in recurrence and survival rates in patients with early-stage (stage I) EEC.
Method: This retrospective study included 234 patients diagnosed with stage I EEC. Considering the demographic information and EEC history, we evaluated the presence of LVSI and its association with recurrence rate, overall survival, and recurrence-free survival. Kaplan-Meier analysis was used to compare survival outcomes between patients with and without LVSI. Statistical analyses were conducted using SPSS software (version 22.0; IBM Corporation, USA). Kaplan-Meier analysis and log-rank tests were used for survival analysis, and P < 0.05 was considered to be significant.
Results: Of 234 patients, 17 relapsed and 8 died. The average time to recurrence was approximately 2.5 years, with vaginal recurrence being the most common. LVSI was identified in 7 patients and was associated with poorer overall survival, but did not predict recurrence-free survival. Patients with LVSI showed a higher risk of recurrence and shorter survival intervals. Stage IA patients with LVSI had relatively high survival probability, while stage IB (myometrial invasion ≥ 50%) patients with LVSI had much poorer outcomes.
Conclusion: LVSI is a critical prognostic factor in early-stage EEC, significantly affecting overall survival. Our study highlights the importance of advanced surveillance and more aggressive treatment for LVSI-positive patients, especially in stage IB. Standardized LVSI assessment and further research are essential to optimize patient management.

Highlights

Zahra Shiravani (google scholar)

Keywords

Main Subjects

Please cite this article as: Najib FS, Yazdanshenas P, Akbarzadeh Jahromi M, Shiravani Z. The prognostic significance of LVSI in early-stage endometrioid endometrial Cancer: Insights into recurrence patterns and survival outcomes. Middle East J Cancer. 2026: in press. doi: 10.30476/mejc.2026.105882.2252.

References
  1. Makker V, MacKay H, Ray-Coquard I, Levine DA, Westin SN, Aoki D, et al. Endometrial cancer. Nat Rev Dis Primers. 2021;7(1):88. doi: 10.1038/s41572-021-00324-8. PMID: 34887451; PMCID: PMC9421940.
  2. Markowska A, Baranowski W, Pityński K, Chudecka-Głaz A, Markowska J, Sawicki W. Metastases and recurrence risk factors in endometrial cancer-the role of selected molecular changes, hormonal factors, diagnostic methods and surgery procedures. Cancers (Basel). 2023;16(1):179. doi: 10.3390/cancers16010179. PMID: 38201606; PMCID: PMC10778296.
  3. Kim JW, Kim JH, Lee YJ. The role of adipokines in tumor progression and its association with obesity. Biomedicines. 2024;12(1):97. doi: 10.3390/biomedicines12010097. PMID: 38255203; PMCID: PMC10813163.
  4. Ajabnoor G, Alsubhi F, Shinawi T, Habhab W, Albaqami WF, Alqahtani HS, et al. Computational approaches for discovering significant microRNAs, microRNA-mRNA regulatory pathways, and therapeutic protein targets in endometrial cancer. Front Genet. 2023;13:1105173. doi: 10.3389/fgene.2022.1105173. PMID: 36704357; PMCID: PMC9872035.
  5. Farzaneh F, Jafari Ashtiani A, Hashemi M, Hosseini MS, Arab M, Ashrafganjoei T, et al. Endometrial cancer in women with abnormal uterine bleeding: Data mining classification methods. Caspian J Intern Med. 2023;14(3):526-33. doi: 10.22088/cjim.14.3.526. PMID: 37520874; PMCID: PMC10379791.
  6. Jones ER, O'Flynn H, Njoku K, Crosbie EJ. Detecting endometrial cancer. Obstet Gynaecol. 2021;23:103-12. doi: 10.1111/tog.12725.
  7. Sia TY, Chen L, Melamed A, Tergas AI, Khoury-Collado F, Hou JY, et al. Trends in use and effect on survival of simple hysterectomy for early-stage cervical cancer. Obstet Gynecol. 2019;134(6):1132-43. doi: 10.1097/AOG.0000000000003552. PMID: 31764729; PMCID: PMC6884101.
  8. Costas L, Frias-Gomez J, Guardiola M, Benavente Y, Pineda M, Pavón MÁ, et al. New perspectives on screening and early detection of endometrial cancer. Int J Cancer. 2019;145(12):3194-206. doi: 10.1002/ijc.32224. PMID: 30714137; PMCID: PMC6850878.
  9. Colombo N, Creutzberg C, Amant F, Bosse T, González-Martín A, Ledermann J, et al. ESMO-ESGO-ESTRO Consensus Conference on endometrial cancer: Diagnosis, treatment and follow-up. Int J Gynecol Cancer. 2016;26(1):2-30. doi: 10.1097/IGC.0000000000000609. PMID: 26645990.
  10. Oaknin A, Bosse TJ, Creutzberg CL, Giornelli G, Harter P, Joly F, et al. Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(9):860-77. doi: 10.1016/j.annonc.2022.05.009. PMID: 35690223.
  11. Wang X, Aziz AuR, Wang D, Wang Y, Liu M, Yu X, et al. Prognostic factors and survival outcomes of immunohistochemically detection based-molecular subtypes of endometrial cancer — analysis of 576 clinical cases. Diagn Pathol. 2024;19(1):162. doi: 10.1186/s13000-024-01584-0. PMID: 39695864; PMCID: PMC11653860.
  12. Bosse T, Peters EEM, Creutzberg CL, Jürgenliemk-Schulz IM, Jobsen JJ, Mens JWM, et al. Substantial lymph-vascular space invasion (LVSI) is a significant risk factor for recurrence in endometrial cancer — A pooled analysis of PORTEC 1 and 2 trials. Eur J Cancer. 2015;51(13):1742-50. doi: 10.1016/j.ejca.2015.05.015. PMID: 26049685.
  13. Oliver-Perez MR, Magriña J, Villalain-Gonzalez C, Jimenez-Lopez JS, Lopez-Gonzalez G, Barcena C, et al. Lymphovascular space invasion in endometrial carcinoma: Tumor size and location matter. Surg Oncol. 2021;37:101541. doi: 10.1016/j.suronc.2021.101541. PMID: 33819820.
  14. Pifer PM, Bhargava R, Patel AK, Ling DC, Vargo JA, Orr BC, et al. Is the risk of substantial LVSI in stage I endometrial cancer similar to PORTEC in the North American population? — A single-institution study. Gynecol Oncol. 2020;159(1):23-9. doi: 10.1016/j.ygyno.2020.07.024. PMID: 32741610.
  15. Stålberg K, Bjurberg M, Borgfeldt C, Carlson J, Dahm-Kähler P, Flöter-Rådestad A, et al. Lymphovascular space invasion as a predictive factor for lymph node metastases and survival in endometrioid endometrial cancer—a Swedish Gynecologic Cancer Group (SweGCG) study. Acta Oncol. 2019;58(11):1628-33. doi: 10.1080/0284186X.2019.1637530. PMID: 31282269.
  16. Buda A, Fruscio R, Mauro J, Imboden S, De Ponti E, Perrone E, et al. The impact of Substantial LYMphovascular space invasion on sentinel lymph nodes status and recurrence in Endometrial Cancer patients: SLYM-EC a multicenter retrospective study. Eur J Surg Oncol. 2024;50(10):108731. doi: 10.1016/j.ejso.2024.108731. PMID: 39305634.
  17. Tortorella L, Restaino S, Zannoni GF, Vizzielli G, Chiantera V, Cappuccio S, et al. Substantial lymph-vascular space invasion (LVSI) as predictor of distant relapse and poor prognosis in low-risk early-stage endometrial cancer. J Gynecol Oncol. 2021;32(3):e31. doi: 10.3802/jgo.2021.32.e31. PMID: 33655767; PMCID: PMC8057046.
  18. Peters EEM, Bartosch C, McCluggage WG, Genestie C, Lax SF, Nout R, et al. Reproducibility of lymphovascular space invasion (LVSI) assessment in endometrial cancer. Histopathology. 2019;75(1):128-36. doi: 10.1111/his.13871. PMID: 31155736; PMCID: PMC6852322.
  19. Peters EEM, Nucci MR, Gilks CB, McCluggage WG, Bosse T. Practical guidance for assessing and reporting lymphovascular space invasion (LVSI) in endometrial carcinoma. Histopathology. 2025;86(2):173-82. doi: 10.1111/his.15272. PMID: 38937066; PMCID: PMC11649510.
  20. Matsuo K, Machida H, Mandelbaum RS, Konishi I, Mikami M. Validation of the 2018 FIGO cervical cancer staging system. Gynecol Oncol. 2019;152(1):87-93. doi: 10.1016/j.ygyno.2018.10.026. PMID: 30409439; PMCID: PMC7265508.
  21. Trojano G, Olivieri C, Tinelli R, Damiani GR, Pellegrino A, Cicinelli E. Conservative treatment in early stage endometrial cancer: a review. Acta Biomed. 2019;90(4):405-10. doi: 10.23750/abm.v90i4.7800. PMID: 31910163; PMCID: PMC7233769.
  22. Faria SC, Devine CE, Rao B, Sagebiel T, Bhosale P. Imaging and staging of endometrial cancer. Semin Ultrasound CT MR. 2019;40(4):287-94. doi: 10.1053/j.sult.2019.04.001. PMID: 31375167.
  23. Evrard C, Alexandre J. Predictive and prognostic value of microsatellite instability in gynecologic cancer (endometrial and ovarian). Cancers (Basel). 2021;13(10):2434. doi: 10.3390/cancers13102434. PMID: 34069845; PMCID: PMC8157359.
  24. Francis SR, Ager BJ, Do OA, Huang Y-HJ, Soisson AP, Dodson MK, et al. Recurrent early stage endometrial cancer: Patterns of recurrence and results of salvage therapy. Gynecol Oncol. 2019;154(1):38-44. doi: 10.1016/j.ygyno.2019.04.676. PMID: 31047753.
  25. de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial. Lancet Oncol. 2019;20(9):1273-85. doi: 10.1016/S1470-2045(19)30395-X. PMID: 31345626; PMCID: PMC6717599.
  26. Moroney MR, Davies KD, Wilberger AC, Sheeder J, Post MD, Berning AA, et al. Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers. Gynecol Oncol. 2019;153(3):517-20. doi: 10.1016/j.ygyno.2019.03.100. PMID: 30954221; PMCID: PMC6559828.
  27. Peters EEM, León-Castillo A, Smit V, Boennelycke M, Hogdall E, Hogdall C, et al. Defining substantial lymphovascular space invasion in endometrial cancer. Int J Gynecol Pathol. 2022;41(3):220-6. doi: 10.1097/PGP.0000000000000806. PMID: 34261899.
Middle East Journal of Cancer

Articles in Press, Accepted Manuscript
Available Online from 01 October 2026
Files
Share
How to cite
Statistics